PHARMACO-KINESIS COMPLETES SUCCESSFUL PROOF-OF-CONCEPT OF MAGNETIC BREATHER PUMP

Inglewood, CA, April 1, 2009 – Pharmaco-Kinesis Corporation, an advanced medical device company developing smart local drug delivery systems, today announced the successful completion of the proof-of-concept benchtop system that demonstrates the viability of the Company's lead project, the Magnetic Breather Pump (MBP).  

"The MBP proof-of-concept 'pathfinder system' assembled by Pharmaco-Kinesis is an important milestone for the Company.  This potentially revolutionary device in the field of drug delivery uses advanced micro-fluidic, diagnostic and control systems to deliver a variable combination of a plurality of tumor fighting medications within one implantable device, " said Josh Shachar, Founder, Director and Chairman of the Scientific Advisory Board of Pharmaco-Kinesis.   "In our first planned application, the MBP is expected to be a quantum leap forward in the treatment of malignant gliomas and other aggressive brain tumors."

The MBP is designed to provide physicians with the remote capability to administer a highly effective therapeutic regimen.  The device is autonomous, self contained, and remotely programmable.  These previously unavailable benefits are expected to significantly improve patient quality of life by freeing the patient from frequent visits to the doctor and eliminating the need for repeated complex brain surgeries to administer tumor-fighting medications.

"We have integrated sophisticated optical sensors and other measurement systems, advanced liquid propulsion systems, microcontrollers, and wireless communications to successfully simulate the final functionality of the MBP," said Thomas C. Chen, M.D., Ph.D., Chief Oncology Officer of Pharmaco-Kinesis.  "The MBP provides metronomic, targeted drug delivery through a regimen programmed by the physician that can be remotely modified based on data from a closed loop "bio-lab" feedback system. This implanted system can potentially eliminate repeated brain surgery procedures required for intratumoral injection of medications, while reducing the cost and increasing the effectiveness of advanced tumor fighting medications through local drug delivery."

One advanced component of the MBP apparatus is a compact "bio-lab" that provides real time measurement of a patient's VEGF (Vascular Endothelial Growth Factor) levels in cerebrospinal or tumor fluid.  Measurement of VEGF levels can indicate whether tumors are growing or shrinking.  This and other information provided through the MBP measurement systems at the tumor site, such as temperature, pressure, pH, and SpO2, can be used to optimize treatment over time.  The Company recently completed the proof-of-concept of the optical lab-on-a-chip. 

Pharmaco-Kinesis is currently working to miniaturize the components of the MBP.  Following miniaturization, the Company will conduct animal studies and plans to work with drug manufacturers to conduct the animal as well as human studies of the MBP.  The biological measurement of tumor response provided by the MBP is expected to enable drug manufacturers to evaluate the effectiveness of their drugs through detailed information on local use, dose, cycle, and circadian time effects of medication, as well as pharmacokinetic and pharmacodynamic behavior. 

Several patents have been filed on the MBP and its components.

For additional information, please contact:
Daniel Saks Senior
Vice President, Corporate Affairs
Pharmaco-Kinesis Corporation
(310) 734-4447